Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Ascendis Pharma (ASND) and Avalo Therapeutics (AVTX)

Tipranks - Tipranks - Fri Mar 6, 6:46AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cytokinetics (CYTK – Research Report), Ascendis Pharma (ASND – Research Report) and Avalo Therapeutics (AVTX – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Cytokinetics (CYTK)

In a report released today, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $101.00. The company’s shares closed last Wednesday at $62.27.

According to TipRanks.com, Timashev is a 5-star analyst with an average return of 14.9% and a 50.6% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. ;'>

Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $95.83, a 57.3% upside from current levels. In a report issued on February 19, Barclays also maintained a Buy rating on the stock with a $87.00 price target.

See today’s best-performing stocks on TipRanks >>

Ascendis Pharma (ASND)

Cantor Fitzgerald analyst Li Watsek maintained a Buy rating on Ascendis Pharma yesterday and set a price target of $300.00. The company’s shares closed last Wednesday at $241.38.

According to TipRanks.com, Watsek is ranked 0 out of 5 stars with an average return of -7.7% and a 38.5% success rate. Watsek covers the Healthcare sector, focusing on stocks such as ArriVent BioPharma, Inc., Tyra Bioscience, and Zai Lab. ;'>

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $293.33, implying a 23.3% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $266.00 price target.

Avalo Therapeutics (AVTX)

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Avalo Therapeutics, with a price target of $48.00. The company’s shares closed last Wednesday at $18.36.

According to TipRanks.com, Rahimi is a 5-star analyst with an average return of 26.2% and a 45.5% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Praxis Precision Medicines, and Crinetics Pharmaceuticals. ;'>

Currently, the analyst consensus on Avalo Therapeutics is a Strong Buy with an average price target of $40.40.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).